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Abstract: Purpose Somatic deletions that affect the lymphoid transcription factor-coding gene IKZF1
have previously been reported as independently associated with a poor prognosis in pediatric B-cell
precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of
IKZF1 deletions by analyzing the effect of co-occurring deletions. Patients and Methods The analysis
involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia
Pediatrica-Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy
number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31
(PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients
from the same trial. Results IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B,
PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were
grouped as IKZF1. The IKZF1 group comprised 6% of patients with BCP ALL, with a 5-year event-free
survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1
definition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ￿ .001). Respective 5-year cumulative
relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ￿ .001). Results were confirmed in
the replication cohort, and multivariable analyses demonstrated independence of IKZF1. The IKZF1
prognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels
after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1 patients was 94 ±
5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1 patients ( P ￿ .001).
Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P
￿ .001). Conclusion IKZF1 describes a new MRD-dependent very-poor prognostic profile in BCP ALL.
Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1 patients, new
experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.
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A B S T R A C T
Purpose
Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1 have previously
been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP)
acute lymphoblastic leukemia (ALL). We have now reﬁned the prognostic strength of IKZF1 de-
letions by analyzing the effect of co-occurring deletions.
Patients and Methods
The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed
Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete in-
formation for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B,
Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of ﬁndings in-
volved 417 patients from the same trial.
Results
IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence
of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1plus. The
IKZF1plus group comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 6
6% comparedwith 796 5% in patients with IKZF1 deletion who did not fulﬁll the IKZF1plus deﬁnition
and 87 6 1% in patients who lacked an IKZF1 deletion (P # .001). Respective 5-year cumulative
relapse incidence rateswere 446 6%, 116 4%, and 106 1% (P# .001). Resultswere conﬁrmed in
the replication cohort, and multivariable analyses demonstrated independence of IKZF1plus. The
IKZF1plus prognostic effect differed dramatically in analyses stratiﬁed by minimal residual disease
(MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1plus
patients was 946 5% versus 40 6 10% in MRD intermediate- and 306 14% in high-risk IKZF1plus
patients (P# .001). Corresponding 5-year cumulative incidence of relapse rates were 66 6%, 606
10%, and 60 6 17% (P # .001).
Conclusion
IKZF1plus describes a new MRD-dependent very-poor prognostic proﬁle in BCP ALL. Because
current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1plus patients, new ex-
perimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.
J Clin Oncol 36:1240-1249. © 2018 by American Society of Clinical Oncology
INTRODUCTION
More than 80% of pediatric patients with B-cell
precursor (BCP) acute lymphoblastic leukemia
(ALL) treated with modern protocols can achieve
a long-term cure, but a signiﬁcant proportion of
these patients still experience relapse and therapy-
related toxicities.1,2 Thus, the focus of therapy
improvement for children with ALL—and any
childhood cancer—is not only cure but also
a minimization of both short- and long-term
therapy-associated toxicities.3,4 These goals can
be achieved with better personalized adjustment
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of therapy to the perceived risk of relapse.5,6 At least 50% of re-
lapses occur among patients classiﬁed as having standard or in-
termediate risk.7,8 Although relapse-prone patients within these
low-risk groups require more-effective therapy, a large number of
the remaining children are most likely overtreated with toxic
chemotherapy. Therefore, a pressing medical need exists for new
prognostic markers to improve risk assessment and tailor treat-
ment in this group of children with ALL.
Triggered by these clinical needs, technical advances in the
ﬁeld of genomic analyses have stimulated a large number of studies
aimed at ﬁnding new biomarkers relevant for risk stratiﬁcation.9-22
A number of candidate markers have been identiﬁed and suggested
as potentially useful for risk stratiﬁcation in childhood ALL. To
date, however, most of these genetic or genomic markers are not
used regularly to support decision making on current clinical
protocols for childhood ALL. General reasons for this lack of
translation include the following: Initial studies have been con-
ducted on small study populations only; study populations have
been selected according to the availability of leukemic specimens
for analysis; studies have been in patient populations that received
heterogeneous and partly outdated treatments; conﬂicting results
have been observed in various studies; and methodological dif-
ferences in marker assessment and uncertainties about assay
procedures exist. Furthermore, when assessed on up-to-date Asso-
ciazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-
Frankfurt-Muenster (AIEOP-BFM) ALL protocols, the prognostic
strength of many new high-risk markers is limited, which makes
exposure to more-intensive and -toxic treatments difﬁcult to justify
for the potential beneﬁt of a minority of patients identiﬁed by the
marker.
The IKZF1 gene encodes Ikaros, a zinc-ﬁnger transcription
factor required for the development of all lymphoid lineages.23
Somatic deletions of IKZF1 have been described as a new high-risk
marker in BCP ALL.24-31 Recently, we and others demonstrated
that activation of JAK-STAT signaling may enhance, whereas de-
letions of ERG can attenuate, the negative prognostic effect con-
ferred by IKZF1 deletions in BCP ALL.28,32-36 The current study
reﬁnes the prognostic strength of IKZF1 deletions and charac-
terizes a new very-poor prognostic subgroup termed IKZF1plus.
IKZF1plus is a combination of previously described gene deletions
and provides additional proof for the importance of moving from
prognostic factors to prognostic proﬁles to sharpen the predictive
strength of newly described genetic markers for integration into
risk-adapted innovative treatment strategies for pediatric ALL.
PATIENTS AND METHODS
Sample Selection
The study included 991 patients with BCP ALL diagnosed between
August 1999 and May 2009 who were enrolled into the international mul-
ticenter trial AIEOP-BFM ALL 2000 for the treatment of pediatric ALL in
Germany and had complete information available for copy number alterations
of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/
Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA genes), and ERG.8,27,37
For independent replication, 417 patients with BCPALL treated in Italy in the
same trial and with comparable genetic data available were analyzed (Fig 1).
In AIEOP-BFM ALL 2000, patients were stratiﬁed into three risk
groups (standard, intermediate, and high). Risk group stratiﬁcation
included minimal residual disease (MRD) analysis and required two
MRD targets with sensitivities of # 1 3 1024. MRD standard-risk
(MRD-SR) patients were MRD negative on treatment days 33 and 78,
and MRD high-risk (MRD-HR) patients had residual disease of $ 5 3
1024 on treatment day 78. All remaining results were considered MRD
intermediate risk (MRD-IR).37 Although MRD analysis was the main
stratiﬁcation criterion in AIEOP-BFM ALL 2000, established high-risk
parameters also were retained as follows: Patients with prednisone poor
response (Table 1),$ 5% leukemic blasts in the bone marrow on day 33,
or positivity for t(4;11) or its molecular equivalent (MLL-AF4 gene
fusion) were stratiﬁed into the high-risk group independent of their
MRD results. Treatment included the use of standard drugs (eg, pred-
nisone, vincristine, daunorubicin, L-asparaginase, cyclophosphamide,
ifosfamide, cytarabine, 6-mercaptopurine, 6-thioguanine, and metho-
trexate) and in some of the patients, cranial irradiation and/or hema-
topoietic stem-cell transplantation (high-risk patients only). For analysis
stratiﬁed according to National Cancer Institute (NCI) criteria, the
deﬁnition of standard risk was an age at diagnosis of 1 year to younger
than 10 years and an initial WBC count of , 50,000/mL; NCI high-risk
patients were 10 years and older and/or had an initial WBC of$ 50,000/mL.
The institutional review boards of Hannover Medical School and all par-
ticipating centers approved the study. Informed consent was obtained in
accordance with the Declaration of Helsinki.
Molecular Genetic Analyses
Copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1,
CDKN2A, CDKN2B, and the Xp22.33/Yp11.31 region (PAR1 region;
CRLF2, CSF2RA, and IL3RA genes; only deletion of CSF2RA and IL3RA
and retention of the CRLF2 probe associated with P2RY8-CRLF2 fusion
that leads to overexpression of CRLF2 was regarded as PAR1 deletion in
this study) were assessed by multiplex ligation-dependent probe ampli-
ﬁcation (MLPA) analyses (SALSA MLPA P335 ALL and P202-A1 IKZF1
kits; MRC-Holland, Amsterdam, the Netherlands). ERG deletion detection
was performed by a custom-made multiplex polymerase chain reaction
assay as described previously.27,36
Statistical Analysis
Differences in the distribution of individual parameters among
patient subsets were analyzed using the x2 or Fisher’s exact test for cat-
egorical variables and the Mann-Whitney U test for continuous variables.
Event-free survival (EFS) was deﬁned as the time from diagnosis to the date
of last follow-up in complete remission (censored time) or ﬁrst event.
Events were resistance to therapy (nonresponse), relapse, secondary
neoplasm, or death as a result of any cause. Failure to achieve remission as
a result of early death or nonresponse was considered as event at time zero.
The Kaplan-Meier method was used to estimate survival rates; differences
were compared using the log-rank test (two-sided).38,39 Cumulative in-
cidence functions for competing events were estimated according to
Kalbﬂeisch and Prentice40 and were compared with Gray’s test.41 The Cox
proportional hazards regression model was used to estimate hazard ratios
and their 95% CIs for prognostic factors.42 Furthermore, the classiﬁcation
and regression tree (CART) method was used to divide successively the
IKZF1-deleted cohort into prognostic subgroups, which split a node into
two subgroups using the covariate that best discriminated the cumulative
incidence of relapse (CIR) on the basis of the lower limit of a one-sided 5%
CI for the risk ratio.43,44 The variable with the highest lower limit was used
for the split. The process stopped when no covariate could split subgroups
farther. Statistical analyses were conducted with SAS-PC 9.1 software (SAS
Institute, Cary, NC). P # .05 was considered statistically signiﬁcant.
Development of Prognostic IKZF1 Deletion Profile
The prognostic effects of IKZF1 deletion in combination with de-
letions in either PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, or
PAR1 were analyzed by separate assessments of CIRs for patients with
jco.org © 2018 by American Society of Clinical Oncology 1241
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IKZF1 deletion compared with those with IKZF1 deletion co-occurring
with one of the deletions mentioned. When numbers within a deletion
subgroup exceeded 10 patients each, heterozygous and homozygous co-
occurrence of a respective deletion with IKZF1 deletion were addressed
separately as well. When numbers were too low or the incidence of relapse
was similar in patients with heterozygous and homozygous deletions, these
groups were combined. Combinations that demonstrated a statistically
signiﬁcant higher CIR than IKZF1 deletion alone in a single analysis
qualiﬁed for integration into the prognostic deletion proﬁle. Deletion
selection for proﬁle integration was further supported using CARTanalysis
to identify deletions that best separate patients with IKZF1 deletions into
risk groups with adverse prognosis.43,44
RESULTS
Initially, we analyzed the association between IKZF1 deletion and
other recurrent deletions observed in ALL by using MLPA data
from 146 of the 991 patients whose ALL cells carried IKZF1 de-
letions. Combined effects on relapse incidence were evaluated for
deletions of IKZF1 with either PAX5, ETV6, RB1, BTG1, EBF1,
CDKN2A, CDKN2B, or those that affected the PAR1 region and led
to CRLF2 overexpression (for deﬁnition of deletions that affect the
PAR1 region, see Patients and Methods, under Molecular Genetic
Analyses). IKZF1 deletions that co-occurred with deletions in
CDKN2A, CDKN2B, PAX5, or the PAR1 region conferred lower
EFS and higher CIRs than their respective negative counterparts
(Appendix Fig A1, online only). ForCDKN2A, a negative effect was
detectable for heterozygous as well as homozygous deletions,
whereas for CDKN2B, only homozygous deletions were of additive
value (Appendix Fig A1). Consequently, all categories of CDKN2A,
CDKN2B, PAX5, or the PAR1 region associated with a dismal
prognosis in the context of IKZF1 deletion were grouped. Deletion
selection for grouping was further supported by CART analysis
(Appendix Fig A2, online only). The additional markers assessed by
MLPA (ETV6, RB1, BTG1, and EBF1) and evaluated for combi-
nation effects were not included for reﬁning IKZF1 status because
no signiﬁcant inﬂuence on outcome was detectable (Appendix Fig
A3, online only). Deletions of ERG attenuate the negative prog-
nostic effect conferred by IKZF1 deletions.35,36 Within the group of
BCP ALL that carry an IKZF1 deletion and at least one additional
unfavorable deletion in CDKN2A, CDKN2B, PAX5, or the PAR1
region, ﬁve patients demonstrated an ERG deletion as well. Thus,
only minimal overlap was observed between the described aber-
ration proﬁle and deletion of ERG. Of note, none of these ﬁve
patients experienced a relapse. The frequency and distribution of
IKZF1 and co-occurring deletions with prognostic effect are
listed in Appendix Table A1 (online only). Consequently, the
ﬁnal deﬁnition of the new prognostic proﬁle termed IKZF1plus
was as follows: deletion of IKZF1 that co-occurred with at least
one additional deletion in CDKN2A, CDKN2B (homozygous
Registered
(N = 4,937)
Eligible for study
(n = 4,839)
Immunophenotype
not available or other
(n = 82)
Not eligible for study (n = 98)
Significant pre treatment (n = 48)
ALL secondary neoplasm (n = 12)
Major medical ailment that prevented protocol therapy (n = 5)
Lack of essential data for establishing the diagnosis (n = 18)
Treatment or start of treatment in a different protocol (n = 8)
Other reasons (n = 7)
B-cell precursor/T-cell ALL
(n = 4,757)
T-cell ALL
(n = 631)
B-cell precursor
(n = 4,126)
German trial cohort
(n = 991)
Italian trial cohort
(n = 417)
Fig 1. Flow diagram of patients in trial AIEOP-BFM
(Associazione Italiana Ematologia ed Oncologia Pediatrica–
Berlin-Frankfurt-Muenster) ALL 2000. ALL, acute lym-
phoblastic leukemia.
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deletion only), PAX5, or PAR1 in the absence of ERG deletion.
Characteristics of IKZF1plus compared with IKZF1 deletions that
did not fulﬁll the IKZF1plus deﬁnition (hereafter called IKZF1
deletion) as well as no IKZF1 deletion are listed in Table 1. Al-
together, IKZF1plus comprised 6% of patients with BCP ALL.
Speciﬁcally, patients with IKZF1plus positivity had higher WBC
counts at diagnosis, were more often positive for CNS disease, and
were rarely ETV6-RUNX1 positive. Their prednisone response and
MRD kinetics were worse than for those who lacked any IKZF1
deletion (Table 1). In an analysis that incorporated 498 patients
with available information, the germline GATA3 single-nucleotide
variant rs3824662, which formerly was related to the risk of de-
veloping B-other or Philadelphia-like pediatric ALL, was associated
with the IKZF1plus group (Table 1).45,46
Table 1. Clinical Characteristics According to IKZF1 Status in 991 Patients With B-Cell Precursor ALL Treated in Germany in Trial AIEOP-BFM ALL 2000
Characteristic
IKZF1 Status, No. (%)
P*No IKZF1 Deletion IKZF1 Deletion IKZF1plus
No. of patients 845 83 63
Sex
Male 447 (52.9) 44 (53.0) 30 (47.6)
Female 398 (47.1) 39 (47.0) 32 (52.4) .718
Age at diagnosis, years
, 10 665 (78.7) 44 (53.0) 39 (61.9)
$ 10 180 (21.3) 39 (47.0) 24 (38.1) , .001
Presenting WBC, count/mL
, 10,000 383 (45.3) 29 (34.9) 10 (15.9)
10,000 to , 50,000 308 (36.4) 38 (45.8) 23 (36.5)
50,000 to , 100,000 93 (11.0) 9 (10.8) 17 (27.0)
$ 100,000 61 (7.2) 7 (8.4) 13 (20.6) , .001
CNS positivity†
No 788 (93.3) 77 (92.8) 55 (87.3)
Yes 21 (2.5) 3 (3.6) 7 (11.1) , .001
Unknown 36 (4.3) 3 (3.6) 1 (1.5)
Hyperdiploidy‡
No 457 (54.8) 53 (63.9) 48 (76.2)
Yes 114 (13.5) 14 (16.9) 4 (6.4) .091
Unknown 274 (32.4) 16 (19.3) 11 (17.5)
ETV6-RUNX1
Negative 587 (69.5) 77 (92.8) 61 (96.8)
Positive 218 (25.8) 3 (3.6) 1 (1.6) , .001
Unknown 40 (4.7) 3 (3.6) 1 (1.6)
MLL-AF4
Negative 840 (99.4) 83 (100) 63 (100)
Positive 5 (0.6) 0 (0.0) 0 (0.0) .649
Prednisone response§
Good 790 (93.5) 68 (81.9) 56 (88.9)
Poor 52 (6.2) 13 (15.7) 7 (11.1) .001
Unknown 3 (0.4) 2 (2.4) 0 (0.0)
MRD risk groupk
Standard 338 (40.0) 15 (18.1) 19 (30.2)
Intermediate 343 (40.6) 37 (44.6) 27 (42.9)
High 28 (3.3) 20 (24.1) 10 (15.9) , .001
Unknown 136 (16.1) 11 (13.3) 7 (11.1)
Final risk group¶
Standard 329 (38.9) 13 (15.7) 19 (30.2)
Intermediate 438 (51.8) 45 (54.2) 33 (52.4)
High 78 (9.2) 25 (30.1) 11 (17.5) , .001
GATA3 rs3824662 genotype
GG 206 (24.4) 23 (27.7) 13 (20.6)
TG 136 (16.1) 17 (20.5) 20 (31.7)
TT 20 (2.4) 4 (4.8) 6 (9.5) .029
Unknown 483 (57.2) 39 (47.0) 24 (38.1)
NOTE. IKZF1plus deﬁnition: presence of IKZF1 deletion and at least an additional deletion in PAX5, CDKN2A, CDKN2B, or PAR1 in the absence of ERG deletion. IKZF1
deletion deﬁnition: IKZF1 deletion present but does not fulﬁll the IKZF1plus deﬁnition.
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; MRD, minimal
residual disease.
*x2 or Fisher’s exact test that compares the groups with various IKZF1 statuses.
†Puncture nontraumatic, WBC count . 5/mL CSF with identiﬁable blasts.
‡Deﬁned by cytogenetics (. 50 chromosomes) or by ﬂow cytometric analyses of the ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes
($ 1.16).
§Good, , 1,000 leukemic blood blasts/mL on treatment day 8; poor, $ 1,000/mL.
kStandard risk, negative on treatment days 33 and 78; high risk, leukemic cell load $ 5 3 1024 on treatment day 78; all other results intermediate risk.
¶Treatment group (for deﬁnition see Patients and Methods, under Sample Selection).
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In outcome analysis, IKZF1plus was associated with a 5-year
EFS of 53 6 6% compared with 79 6 5% in patients with IKZF1
deletion or 87 6 1% in patients who lacked any IKZF1 deletion
(IKZF1plus v no IKZF1 deletion, P # .001; Fig 2A). The respective
5-year CIRs were 446 6%, 116 4%, and 106 1% (IKZF1plus v no
IKZF1 deletion, P # .001; Fig 2C). Appendix Fig A4 (online only)
shows the poor prognostic effect of IKZF1plus in analyses stratiﬁed
by NCI risk group and patients with high initial WBC counts of
$ 50,000/mL and $ 100,000/mL. Multivariable analyses that in-
cluded variables of clinical and prognostic relevance previously de-
scribed in AIEOP-BFM ALL 200037 demonstrated independence
of IKZF1plus—with IKZF1plus conferring the largest hazard ratio for
relapse—and underscored its strong prognostic effect (Table 2).
We next used an independent cohort of 417 patients treated in
AIEOP-BFM ALL 2000 in Italy who had the necessary genetic
information available for conﬁrmation of the negative prognostic
effect of IKZF1plus (Appendix Table A2, online only). The 5-year
EFS observed for IKZF1plus was 446 12% compared with 746 7%
for IKZF1 deletions or 856 2% for no IKZF1 deletions (IKZF1plus
v no IKZF1 deletion, P# .001; Fig 2B). The respective 5-year CIRs
were 44 6 12%, 24 6 7%, and 13 6 2% (IKZF1plus v no IKZF1
deletion, P = .001; Fig 2D). Similar to the observation cohort,
multivariable analyses in the validation cohort demonstrated in-
dependence of IKZF1plus (Appendix Table A3, online only).
We have previously demonstrated that MRD risk group (for
deﬁnition, see Patients and Methods, under Sample Selection) is
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Fig 2. Event-free survival (EFS) and cumulative incidence of relapse (CIR) at 5 years according to IKZF1 status (no IKZF1 deletion [IKZF1 del], IKZF1 del, IKZF1plus) in
patients with B-cell precursor acute lymphoblastic leukemia (ALL) treated in trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-
Muenster) ALL 2000. (A) EFS in 991 patients from the observational cohort recruited in Germany. (B) EFS in 417 patients from the replication cohort recruited in Italy. (C) CIR
in the observational cohort. (D) CIR in the replication cohort. del, deletion.
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the strongest prognostic factor in our protocol.37 Therefore, we
assessed the prognostic effect of IKZF1plus in the context of
treatment response and treatment intensity. Unexpected dramatic
differences among MRD risk groups were detected in these ana-
lyses: The 5-year EFS for MRD-SR IKZF1plus patients was 946 5%
compared with 406 10% in MRD-IR and 306 14% in MRD-HR
IKZF1plus patients; the corresponding 5-year CIRs were 6 6 6%,
60 6 10%, and 60 6 17%. Figure 3 demonstrates these results for
IKZF1plus compared with IKZF1 deletions and no IKZF1 deletions.
When the type and number of deletions in IKZF1plus were assessed
by MRD risk group to explain the observed differential prognostic
effect (Appendix Tables A4 and A5, online only), neither obvious
differences in type nor signiﬁcant differences in number of de-
letions (P = .750) were detected among the MRD risk groups.
Finally, we analyzed whether we could detect changes in aberration
proﬁles of IKZF1plus samples from initial diagnosis to relapse. For
this purpose, we compared 14 samples with MLPA analyses from
both time points and did not identify recurrent proﬁle changes
(Appendix Table A6, online only). Taken together, IKZF1plus
conferred an extremely high risk of relapse, speciﬁcally to MRD-IR
and MRD-HR patients.
DISCUSSION
We deﬁne a new and powerful prognostic proﬁle, IKZF1plus, for
pediatric ALL treated with BFM therapy-based clinical protocols.
The use of IKFZ1 deletion in combination with speciﬁc additional
single genetic deletions provides an independent strong molecular
stratiﬁcation marker in addition to MRD measurements. The
extremely poor outcome of patients treated by either intermediate-
or high-intensity chemotherapy suggests thatMRD-IR andMRD-HR
IKZF1plus patients should be enrolled in clinical trials that incorporate
and evaluate experimental therapies.
Research on the clinical and biologic aspects of ALL has
identiﬁed numerous prognostic factors used in modern clinical
protocols to stratify patients according to their probability of
treatment failure into risk groups of various treatment intensities
(eg, standard/low, intermediate, high).1,2 During the past two
decades, molecular monitoring of MRD in AIEOP-BFM studies
has become the most important prognostic factor.8,37 However,
although a poor early response to therapy as characterized by our
MRD-HR deﬁnition predicts treatment failure and deﬁnes a true
high-risk patient population, the majority of recurrences are still
observed in the large group of MRD-IR patients. In AIEOP-BFM
ALL 2000, 69% of BCP ALL relapses occurred in these patients,
which exempliﬁes that for a majority of patients with disease
recurrence, the precedent treatment stratiﬁcation strategy does not
adequately reﬂect their actual risk of relapse.8,37 Consequently,
current treatment stratiﬁcation still needs improvement to lead to
a more-precise early characterization of the patient at true risk of
relapse. Upfront identiﬁcation of these patients is essential in future
clinical trials for optimal therapy early on and for high-risk pa-
tients, the timely introduction of innovative treatment options,
such as immunotherapy.47 IKZF1plus represents a simple pragmatic
approach to addressing this dilemma: The group comprised ap-
proximately 6% of patients with BCP ALL, which accounts for
approximately 25% of relapses; the majority of the relapses oc-
curred in MRD-IR patients. Therefore, the use of this new bio-
marker is directly applicable to clinical practice to improve risk
stratiﬁcation of patients treated in AIEOP-BFM ALL trials.
Several studies have linked IKZF1 deletions to an unfavorable
clinical outcome of BCP ALL in various treatment protocols,
including those that used risk stratiﬁcation guided by MRD
monitoring.24-36,48-51 As a consequence, international study groups
have included IKZF1 deletion status in their high-risk treatment
stratiﬁcation strategies for patients with BCP ALL.48,49 However,
other study groups, including AIEOP-BFM, currently do not
Table 2. Estimated HRs From the Multivariable Cox Proportional Hazards Model on Event-Free Survival and Hazard of Relapse in Patients With B-Cell Precursor ALL
From Trial AIEOP-BFM ALL 2000
Variable
Event Relapse
HR 95% CI P HR 95% CI P
IKZF1plus* 2.62 1.41 to 4.86 .002 4.00 1.91 to 8.37 , .001
IKZF1 deletion† 1.03 0.60 to 1.76 .928 0.85 0.44 to 1.67 .639
ETV6-RUNX1 positivity‡ 0.97 0.60 to 1.56 .903 1.03 0.62 to 1.70 .908
MRD standard risk§ 0.49 0.31 to 0.77 .002 0.42 0.26 to 0.68 , .001
MRD high risk§ 3.42 2.07 to 5.65 , .001 2.04 1.10 to 3.81 .024
Slow early MRD responsek 2.70 1.64 to 4.44 , .001 2.69 1.60 to 4.53 , .001
Poor prednisone response¶ 1.13 0.68 to 1.88 .633 0.94 0.51 to 1.72 .840
Presenting WBC# count $ 100,000/mL 2.36 1.49 to 3.74 , .001 2.59 1.56 to 4.28 , .001
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; HR, hazard ratio;
MRD, minimal residual disease.
*Presence of IKZF1 deletion and at least an additional deletion in PAX5, CDKN2A, CDKN2B, or PAR1 in the absence of ERG deletion. HR compared with patients who
lacked an IKZF1 deletion.
†IKZF1 deletion present but does not fulﬁll the IKZF1plus deﬁnition. HR compared with patients who lacked an IKZF1 deletion.
‡Compared with ETV6-RUNX1 negativity.
§MRD standard risk, negative on treatment days 33 and 78; MRD high risk, leukemic cell load$ 53 1024 on treatment day 78; all other results MRD intermediate risk.
HR compared with other MRD groups.
kMRD $ 5 3 1024 on treatment day 33 and positivity of , 5 3 1024 on treatment day 78. HR compared with MRD intermediate-risk patients with no slow early
response.
¶Leukemic blasts $ 1,000/mL in the peripheral blood on treatment day 8. HR compared with patients with , 1,000/mL leukemic blasts.
#HR compared with patients with presenting WBC counts , 100,000/mL.
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Fig 3. Event-free survival (EFS) and cumulative incidence of relapse (CIR) at 5 years according to IKZF1 status (no IKZF1 deletion [IKZF1 del], IKZF1 del, IKZF1plus) in 837 patients with
B-cell precursor acute lymphoblastic leukemia (ALL) with available minimal residual disease (MRD) data treated in trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia
Pediatrica–Berlin-Frankfurt-Muenster) ALL2000.MRDstandard-risk (MRD-SR) patientswereMRDnegative on treatment days33and78;MRDhigh-risk (MRD-HR) patientshad leukemic cell
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follow this strategy because the prognostic effect of IKZF1 deletions
is judged as not profound enough to justify exposure to the toxic adverse
effects of high-risk treatment of a majority of actual intermediate-risk
patients not in need of treatment intensiﬁcation.27,33,52 By the
deﬁnition of IKZF1plus, we reﬁned the prognostic strength of
IKZF1 deletions by describing a very-poor prognostic IKZF1
deletion–associated genetic aberration proﬁle that now, in combi-
nation with MRD analyses, justiﬁes clinical implementation as
a high-risk stratiﬁcation criterion in frontline AIEOP-BFM trials
for the treatment of ALL.
Despite these promises, there are limitations with our ap-
proach. First, besides polymerase chain reaction analysis for ERG
deletions, our study used MLPA-based assessment of leukemic
copy number aberrations. This assay has a limited sensitivity to
detect less-abundant subclonal lesions (, 30%). However, the
prognostic signiﬁcance of these subclonal lesions is unclear, and
the relevance of their exact quantiﬁcation currently is a matter of
debate.49,53 Second, although we initiated our analysis with 991
patients, we may have missed additional prognostically relevant
deletions as a result of a lack of power. In this context, continued
analyses, including the pooling of copy number variation data
across study groups, will secure identiﬁcation of additional
combinations with prognostic effect. Third, in our simple ap-
proach, we only incorporated the data available to us, which led to
a restricted view by potentially excluding additional relevant
information. The capture of broader information by more-
comprehensive genomic techniques could further expand and
strengthen the IKZF1plus proﬁle. Fourth, we lacked information on
other relevant prognostic subgroups. For example, IKZF1 deletions
frequently are found in Philadelphia-like and BCR-ABL1–like ALL,
two related subgroups characterized by tyrosine kinases or cyto-
kine receptor activation. Indeed, Roberts et al54 described a neg-
ative prognostic effect for IKZF1 deletions in Philadelphia-like
ALL. In contrast, a similar effect could not be observed by van der
Veer et al48 when analyzing the role of IKZF1 deletions in BCR-
ABL1–like ALL. Finally, because of a lack of systematic assessment,
we were not able to compare our approach with other existing ones
that integrated IKZF1 deletion status with molecular and/or
conventional diagnostic genetic information with or without
MRD data.33,49,50 For example, we did not routinely analyze IGH-
CRLF2 fusions in our cohort and, therefore, cannot judge their
possible prognostic signiﬁcance alone or in the context of IKZF1
deletion. Future, more-comprehensive prospective studies will
need to determine the potential interactions of IKZF1plus with
kinase-activating and other poor prognosis genetic aberrations in
our trials.
One intriguing observation related to IKZF1plus is the strong
dependence of its prognostic effect on MRD. In MRD-SR patients
with no measurable MRD after induction, treatment outcome was
not negatively affected by the presence of IKZF1plus, whereas patients
with measureable MRD (MRD-IR, MRD-HR) faced a 10-fold higher
relapse rate. Previous studies, including ours, described an association
of IKZF1 deletion andMRD in ALL. However, the effects observed in
these studies were not comparable with regard to the dramatic extent
observed in the current study,27,33,52 or studies were performed under
different conditions with regard to MRD assessment, risk stratiﬁ-
cation, or treatment.46,51,55 Hypothetical explanations for the effect
observed in the current study could be different distributions of either
additional leukemic aberrations or underlying hereditary factors in
MRD-SR compared with MRD-IR and MRD-HR patients. Future
research efforts will need to discover the mechanism that underlies
the differential prognostic effect of IKZF1plus in various MRD risk
groups.
With speculation on the characteristics that unify IKZF1plus
patients as a subgroup, the ALL risk-conferring GATA3 single-
nucleotide variant rs382466245,46 was found to be enriched
within IKZF1plus patients. This may point to a common he-
reditary background in these patients, which needs additional
characterization.
In conclusion, we have integrated molecular genetic data
with MRD data into a single combined classiﬁcation that will be
used to reﬁne treatment stratiﬁcation and guide innovative but
still costly therapeutic applications in our upcoming trial
AIEOP-BFM ALL 2017 for frontline treatment of pediatric ALL.
To go beyond current risk stratiﬁcation strategies, additional
research on the biologic basis of our observations is needed and
will be helpful in guiding the development of more-targeted and
less-toxic innovative therapies for children and adolescents with
ALL.
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Fig A1. Cumulative relapse incidence (CIR) at ﬁve years in B-cell precursor ALL patients treated on trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia
Pediatrica–Berlin-Frankfurt-Muenster) ALL 2000 according to IKZF1 status alone or in combination with (A) heterozygous or homozygous CDKN2A deletion, (B) het-
erozygous or homozygous PAX5 deletion, (C) PAR1 deletion, (D) homozygous CDKN2B deletion. (E) and (F) show CDKN2A and CDKN2B wild-type, heterozygous and
homozygous deletions separately. (*) Fourteen patients with heterozygous (het) PAX5 deletion, one patient with homozygous (hom) PAX5 deletion (del). pCIR, estimated
cumulative incidence of relapse.
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Fig A2. Classiﬁcation and regression tree analysis of sequentially subclassiﬁed
patients by genetic data from multiplex ligation-dependent probe ampliﬁcation
analysis that included PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, or PAR1
for the 146 patients with IKZF1 deletion (del) from AIEOP-BFM (Associazione
Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster) Acute
Lymphoblastic Leukemia (ALL) 2000 for whom these data were available. The
most discriminatory variable at each point is selected by the classiﬁcation and
regression tree algorithm. The groups were deﬁned by the observed incidence of
relapse within each node of the graph for deleted and nondeleted cases, re-
spectively. Relapse risk ratio (RR) and lower-level CIs (LL) are presented. het,
heterozygous; hom, homozygous.
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Fig A3. Cumulative relapse incidence (CIR) at ﬁve years in B-cell precursor ALL patients treated on trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia
Pediatrica–Berlin-Frankfurt-Muenster) ALL 2000 according to IKZF1 status alone or in combination with (A) heterozygous or homozygous ETV6 deletion, (B) heterozygous
or homozygous RB1 deletion, (C) heterozygous or homozygous BTG1 deletion, (D) heterozygous or homozygous EBF1 deletion. pCIR, estimated cumulative incidence of
relapse. del, deletion; het, heterozygous; hom, homozygous.
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Fig A4. Cumulative relapse incidence (CIR) at ﬁve years in B-cell precursor ALL patients treated on trial AIEOP-BFM (Associazione Italiana Ematologia ed Oncologia
Pediatrica–Berlin-Frankfurt-Muenster) ALL 2000 stratiﬁed by white blood cell (WBC) count and NCI risk groups according to IKZF1 status (no IKZF1 deletion, IKZF1-deleted,
IKZF1plus). NCI standard-risk patientswere one to younger than ten years and had an initialWBC count of, 50,000/ml, NCI high-risk patientswere ten years and older and/or
had an initial WBC of $ 50,000/ml. CIR in (A) NCI standard-risk patients, (B) NCI high-risk patients, (C) patients with initial WBC counts $ 50,000/ml, and (D) patients with
initial WBC counts of $ 100,000/ml. pCIR, estimated cumulative incidence of relapse. del, deletion.
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Table A1. Deletion Matrix for 991 German Patients With B-Cell Precursor ALL Treated in Trial AIEOP-BFM ALL 2000
Deletion Combination*
No IKZF1 del IKZF1 del†
IKZF1plus‡ERG del Negative ERG del Positive ERG del Negative ERG del Positive
CDKN2A wild type
PAX5 wild type
CDKN2B wild type
PAR1 wild type 516 22 57 19
PAR1 del 4 — — 9
CDKN2B het del
PAR1 wild type 5 — 1 1
CDKN2B hom del
PAR1 wild type 2 —
PAX5 het or hom del
CDKN2B wild type
PAR1 wild type 65 3 1 9
PAR1 del 3 — 2
CDKN2B hom del
PAR1 wild type 1 —
CDKN2A het del
PAX5 wild type
CDKN2B wild type
PAR1 wild type 12 1 2
PAR1 del 1 —
CDKN2B het del
PAR1 wild type 53 2 1 5
PAR1 del 1 —
CDKN2B hom del
PAR1 wild type 8 — 2
PAR1 del 1 —
PAX5 het or hom del
CDKN2B wild type
PAR1 wild type 2 — 1
CDKN2B het del
PAR1 wild type 22 3 2 4
PAR1 del 1 — 2
CDKN2B hom del
PAR1 wild type 8 — 2
PAR1 del 2 — 1
CDKN2A hom del
PAX5 wild type
CDKN2B wild type
PAR1 wild type 1 —
PAR1 del 1 —
CDKN2B het del
PAR1 wild type 6 1 3
PAR1 del — — 1
CDKN2B hom del
PAR1 wild type 39 1 7
PAR1 del 3 —
PAX5 het or hom del
CDKN2B wild type
PAR1 wild type 2 —
CDKN2B het del
PAR1 wild type 10 — 5
PAR1 del 2 —
CDKN2B hom del
PAR1 wild type 38 — 1 8
PAR1 del 3 —
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; del, deletion;
het, heterozygous; hom, homozygous.
*On the basis of multiplex ligation-dependent probe ampliﬁcation analysis for IKZF1, CDKN2A, PAX5, CDKN2B, and PAR1 according to genomic polymerase chain
reaction for ERG.
†IKZF1 del present but does not fulﬁll the IKZF1plus deﬁnition.
‡Presence of IKZF1 del and at least an additional deletion in PAX5, CDKN2A, CDKN2B, or PAR1 in the absence of ERG del.
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Table A2. Clinical Characteristics According to IKZF1 Status in 417 Italian Patients With Precursor B-Cell ALL Treated in Trial AIEOP-BFM ALL 2000
Characteristic
IKZF1 Status, No. (%)
P*No IKZF1 Deletion IKZF1 Deletion IKZF1plus
No. of patients 357 42 18
Sex
Male 188 (52.7) 22 (52.4) 8 (44.4)
Female 169 (47.3) 20 (47.6) 10 (55.6) .793
Age at diagnosis, years
, 10 307 (86.0) 28 (66.7) 12 (66.7)
$ 10 50 (14.0) 14 (33.3) 6 (33.3) .001
Presenting WBC, count/mL
, 10,000 199 (55.7) 18 (42.9) 5 (27.8)
10,000 to , 50,000 111 (31.1) 18 (42.9) 5 (27.8)
50,000 to , 100,000 23 (6.4) 2 (4.8) 5 (27.8)
$ 100,000 24 (6.7) 4 (9.5) 3 (16.7) , .001
CNS disease†
Negative 357 (100) 42 (100) 18 (100) —
Positive — — —
Other/unknown — — —
Hyperdiploidy‡
No 251 (70.3) 33 (78.6) 17 (94.4)
Yes 81 (22.7) 5 (11.9) — .023
Unknown 25 (7.0) 4 (9.5) 1 (5.6)
ETV6-RUNX1
Negative 257 (72.0) 38 (90.5) 17 (94.4)
Positive 82 (23.0) — 1 (5.6) , .001
Unknown 18 (5.0) 4 (9.5) —
MLL-AF4
Negative 352 (98.6) 42 (100) 18 (100)
Positive 3 (0.8) — — .775
Unknown 2 (0.6) — —
Prednisone response§
Good 333 (93.3) 39 (92.9) 17 (94.4)
Poor 21 (5.9) 3 (7.1) — .550
Unknown 3 (0.8) — 1 (5.6)
MRDk
TP1 and TP2 negative 116 (32.5) 5 (11.9) 3 (16.7)
Other 162 (45.4) 20 (47.6) 8 (44.4)
TP2 $ 1023 3 (0.8) 6 (14.3) — , .001
Unknown 76 (21.3) 11 (26.2) 7 (38.9)
Final risk group¶
SR 109 (30.5) 5 (11.9) 3 (16.7)
IR 222 (62.2) 30 (71.4) 12 (66.7)
HR 26 (7.3) 7 (16.7) 3 (16.7) , .001
NOTE. IKZF1plus deﬁnition: presence of IKZF1 deletion and at least an additional deletion in PAX5, CDKN2A, CDKN2B, or PAR1 in the absence of ERG deletion. IKZF1
deletion deﬁnition: IKZF1 deletion present but does not fulﬁll the IKZF1plus deﬁnition.
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; HR, high risk;
IR, intermediate risk; MRD, minimal residual disease; SR, standard risk; TP, time point.
*x2 or Fisher’s exact test that compares the groups with various IKZF1 statuses.
†CNS negative, puncture nontraumatic without leukemic blasts in the CSF after cytocentrifugation; CNS positive, puncture nontraumatic with WBC . 5/mL in the CSF
with identiﬁable blasts.
‡Deﬁned by cytogenetics (. 50 chromosomes) or by ﬂow cytometric analyses of the ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes
($ 1.16).
§Good, , 1,000 leukemic blood blasts/mL on treatment day 8; poor, $ 1,000/mL.
kTP1, treatment day 33; TP2, treatment day 78; MRD $ 1023 qualiﬁes for the MRD-HR group.
¶For deﬁnition of risks, see Patients and Methods, under Sample Selection.
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Table A3. Estimated HRs From the Multivariable Cox Proportional Hazards Model on Event-Free Survival and Hazard of Relapse in Patients With B-Cell Precursor
ALL in Trial AIEOP-BFM ALL 2000
Variable
Event Relapse
HR 95% CI P HR 95% CI P
IKZF1plus* 2.95 1.02 to 8.55 .046 3.16 1.08 to 9.28 .036
IKZF1 deletion† 0.85 0.38 to 1.88 .688 0.84 0.37 to 1.90 .681
ETV6-RUNX1 positivity‡ 2.26 0.95 to 5.34 .064 2.12 0.89 to 5.05 .088
MRD standard risk§ 0.34 0.16 to 0.71 .004 0.36 0.17 to 0.76 .004
MRD high risk§ 23.49 6.82 to 80.85 , .001 33.53 9.67 to 116.30 .018
Slow early MRD responsek 2.08 1.08 to 4.02 .029 2.22 1.14 to 4.31 .018
Poor prednisone response¶ 0.40 0.10 to 1.56 .186 0.29 0.06 to 1.31 .107
Presenting WBC# count $ 100,000/mL 1.18 0.40 to 3.43 .767 1.07 0.34 to 3.36 .907
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; HR, hazard ratio;
MRD, minimal residual disease.
*Presence of IKZF1 deletion and at least an additional deletion in PAX5, CDKN2A, CDKN2B, or PAR1 in the absence of ERG deletion. HR compared with patients who
lacked an IKZF1 deletion.
†IKZF1 deletion present but does not fulﬁll the IKZF1plus deﬁnition. HR compared with patients who lacked an IKZF1 deletion.
‡HR compared with ETV6-RUNX1 negative.
§MRD standard risk, negative on treatment days 33 and 78; MRD high risk, leukemic cell load$ 53 1024 on treatment day 78; all other results MRD intermediate risk.
HR compared with other MRD groups.
kMRD $ 5 3 1024 on treatment day 33 and positivity of , 5 3 1024 on treatment day 78. HR compared with MRD intermediate risk patients with no slow early
response.
¶Leukemic blasts $ 1,000/mL in the peripheral blood on treatment day 8. HR compared with patients with , 1,000/mL leukemic blasts.
#HR compared with patients with presenting WBC counts , 100,000/mL.
Table A4. Deletions in IKZF1plus Patients in Trial AIEOP-BFM ALL 2000 by
Various MRD Groups
Type of Deletion
MRD Group*, No. (%)
SR IR HR Unknown
No. of patients 19 27 10 7
CDKN2A wild type 5 (26.3) 9 (33.3) 3 (30.0) 3 (42.9)
CDKN2A het or hom del 14 (73.7) 18 (66.6) 7 (70.0) 4 (57.1)
PAX5 wild type 6 (31.6) 11 (40.7) 7 (70.0) 5 (71.4)
PAX5 het or hom del 13 (68.4) 16 (59.3) 3 (30.0) 2 (28.6)
CDKN2B wild type or het del 12 (63.2) 19 (70.4) 6 (60.0) 6 (85.7)
CDKN2B hom del 7 (36.8) 8 (29.6) 4 (40.0) 1 (14.3)
PAR1 wild type 15 (78.9) 20 (74.1) 9 (90.0) 5 (71.4)
PAR1 del 4 (21.1) 7 (25.9) 2 (20.0) 2 (28.6)
NOTE. On the basis of a multiplex ligation-dependent probe ampliﬁcation
analysis. IKZF1plus deﬁnition: presence of IKZF1 deletion and at least an additional
deletion in PAX5 (het or hom), CDKN2A (het or hom), CDKN2B (hom only), or
PAR1 (het or hom) in the absence of ERG deletion (het or hom).
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia
Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; del,
deletion; het, heterozygous; hom, homozygous; HR, high risk; IR, intermediate
risk; MRD, minimal residual disease; SR, standard risk.
*MRD-SR, negative on treatment days 33 and 78; MRD-HR, leukemic cell load
$ 5 3 1024 on treatment day 78; all other results MRD-IR.
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Table A6. Genes Affected in Deletion Patterns at Initial Diagnosis and at Relapse in 14 IKZF1plus Patients
Sample Pair Initial Diagnosis Relapse Diagnosis
1 IKZF1 het, PAX5 het IKZF1 het, CDKN2A het, CDKN2B het, PAX5 het
2 IKZF1 het, CDKN2A hom, CDKN2B hom, PAX5 het IKZF1 het, CDKN2A het, CDKN2B het
3 IKZF1 het, PAX5 het IKZF1 het, PAX5 het
4 IKZF1 het, PAR1 het IKZF1 het
5 IKZF1 het, PAR1 het IKZF1 het
6 IKZF1 het, PAX5 het IKZF1 het, CDKN2A het, CDKN2B hom, PAX5 hom
7 IKZF1 het, CDKN2A hom, CDKN2B het, PAX5 het IKZF1 het, CDKN2A hom, CDKN2B het, PAX5 het
8 IKZF1 hom, CDKN2A hom, CDKN2B hom IKZF1 hom, CDKN2A hom, CDKN2B hom
9 IKZF1 het, PAX5 het IKZF1 het, PAX5 het
10 IKZF1 het, PAR1 het IKZF1 het, PAR1 het
11 IKZF1 het, CDKN2A het, CDKN2B hom, PAX5 het IKZF1 het, CDKN2A het, CDKN2B hom, PAX5 het
12 IKZF1 het, CDKN2A hom, CDKN2B het IKZF1 het, CDKN2A het, CDKN2B het
13 IKZF1 het, CDKN2A het, CDKN2B hom, PAX5 hom, PAR1 het IKZF1 het, CDKN2A het, CDKN2B hom, PAX5 hom, PAR1 het
14 IKZF1 het, PAX5 het IKZF1 het, PAX5 het
NOTE. On the basis of amultiplex ligation-dependent probe ampliﬁcation analysis, includingCDKN2A, PAX5,CDKN2B, and PAR1. IKZF1plus deﬁnition: presence of IKZF1
deletion and at least an additional deletion in PAX5 (het or hom), CDKN2A (het or hom), CDKN2B (hom only), or PAR1 (het or hom) in the absence of ERG deletion
(het or hom).
Abbreviations: het, heterozygous; hom, homozygous.
Table A5. Number of Unfavorable Deletions in Addition to IKZF1 in IKZF1plus
Patients in Trial AIEOP-BFM ALL 2000 by Various MRD Groups
No. of deletions
MRD Group*, No. (%)
SR IR HR Unknown
No. of patients 19 27 10 7
One deletion 6 (31.6) 12 (44.4) 5 (50.0) 5 (71.4)
Two deletions 7 (36.8) 9 (33.3) 4 (40.0) 2 (28.6)
Three deletions 6 (31.6) 5 (18.5) 1 (10.0) —
Four deletions — 1 (3.7) — —
NOTE. On the basis of a multiplex ligation-dependent probe ampliﬁcation analysis,
including CDKN2A, PAX5,CDKN2B, and PAR1. IKZF1plus deﬁnition: presence of IKZF1
deletion and at least an additional deletion inPAX5 (het or hom),CDKN2A (het or hom),
CDKN2B (homonly), or PAR1 (het or hom) in the absenceofERGdeletion (het or hom).
Abbreviations: AIEOP-BFM, Associazione Italiana Ematologia ed Oncologia
Pediatrica–Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukemia; het,
heterozygous; hom, homozygous; HR, high risk; IR, intermediate risk; MRD,
minimal residual disease; SR, standard risk.
*MRD-SR, negative on treatment days 33 and 78; MRD-HR, leukemic cell load
$ 53 1024 on treatment day 78; all other results MRD-IR. P = .750 by x2 test for
comparison of the various MRD groups for differences in number of deletions.
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